Ablexis Raises $12 Million
Ablexis LLC, a San Francisco-based developer of a platform for antibody drug discovery, has raised $12 million in Series A funding. Third Rock Ventures led the round, and was joined by Pfizer Venture Investments.
2 June 2010•4 mins read
